Navigation Links
MEDIA ALERT: Eularis to Address Marketing Return at Pharmaceutical Marketing Society Half-day Conference: ROI or RIP?
Date:11/20/2007

WHO: Eularis

WHAT: Presentation on Marketing Return: What can be measured?

WHEN: 26 November 2007 at 2:30 p.m. GMT WHERE: Pharmaceutical Marketing Society Half-day Conference, 20 Cavendish

Square, London

NEW YORK and LONDON, Nov. 20 /PRNewswire/ -- Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on marketing return at the Pharmaceutical Marketing Society Half-day Conference: ROI or RIP.

*(LOGO 72dpi: Send2Press.com/mediaboom/07-0924-Eularis_72dpi.jpg)

At 2:30 p.m. on Monday 26 November 2007, Dr. Bates will deliver a presentation titled, "What Can Be Measured?" Bates will challenge the thinking of conference attendees and will expose where ROI goes wrong, the limitations of ROI and what can and should be measured. She will also provide attendees with ideas on how to put ROI to work in their own pharmaceutical organizations.

Bates has gained wide recognition within the international pharmaceutical industry for her expertise in marketing return analysis. Under Bates' leadership, Eularis issued two related research reports this year, including Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things? (http://www.pharmaindustrysfe.com/) and Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line (http://www.pharmamarketingroi.com/).

The Pharmaceutical Marketing Society Half-day Conference takes place in London. The conference will be focused on answering two pivotal questions: "Are you maximising the return on investment from your marketing spend?" and "Do you know where your marketing spend is having the most effect?" For more information, visit: http://www.pmsociety.org.uk/events/roi.

To arrange an interview with Eularis, please contact Jennifer Humiston at +1 617.779.1812 or via email at jhumiston@shiftcomm.com.

About Eularis

Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis' proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance. Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions. Co-headquartered in London and New York City, the company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit http://www.eularis.com.

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Eularis
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AUDIO from Medialink and Radica: Staying Sharp with Games for Your Brain
2. AUDIO from Medialink and Kelloggs: Whats in Your Water?
3. AUDIO from Medialink and Commit Lozenge: Wanna Quit Smoking With Therapeutic Nicotine? Just Follow the Directions
4. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
5. Justice Department to Hold Media Event to Demonstrate New Database for Matching Unidentified Remains and Missing Persons Information
6. Weiner Public News First Media Team at National Press Club 5K
7. VIDEO from Medialink and General Motors: On and Off the Track
8. HealthMedia Revolution Explodes in Second Quarter
9. AUDIO from Medialink and Pfizer: Prescription for Safer Drugs Discussed in Washington
10. AUDIO from Medialink and Allergan: Women Not Sure Who to Trust on Anti-Aging Skin Care
11. AUDIO from Medialink and Pfizer: A New Prescription for Safer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... miniature, folded, pharmaceutical inserts and outserts. As a means of expanding capabilities ... addition will enable Flottman to individually code professional inserts (PIs) and patient package ...
(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...
(Date:12/9/2016)... ... 09, 2016 , ... The Holy Name Medical Center Foundation ... on December 3rd, to benefit Holy Name Medical Center's programs and services. More ... over $1 million - the largest event in the Center's history, both in ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)... 2016 KEY FINDINGS The global ... 2017-2023. Various reasons for growth of the medical lifting ... of chronic diseases, high recovery cost of injuries and ... Medical lifting sling refers to an assistive device that ... slings connect to the lift and hold the patient. ...
(Date:12/8/2016)... Lilly and Company (NYSE: LLY ) today ... at the 9 th Clinical Trials on Alzheimer,s ... meet the primary endpoint in the EXPEDITION3 clinical trial, ... dementia due to Alzheimer,s disease (AD), and Lilly will ... of mild dementia due to AD. ...
Breaking Medicine Technology: